Long-read Oxford Nanopore sequencing enables rapid, cost-effective, and comprehensive TTR genetic testing for hereditary transthyretin amyloidosisGilles Millaton May 19, 2026 at 10:00 am

Clin Chem Lab Med. 2026 May 20. doi: 10.1515/cclm-2026-0553. Online ahead of print.

ABSTRACT

OBJECTIVES: Hereditary transthyretin amyloidosis (ATTRv) is a rare autosomal dominant disorder caused by pathogenic variants in the TTR gene, with marked clinical heterogeneity and frequent underdiagnosis. Genetic confirmation is essential for patient management but is traditionally based on Sanger sequencing or short-read next-generation sequencing (NGS), which are time-consuming or costly. We evaluated the clinical utility of a long-read sequencing strategy using Oxford Nanopore Technologies (ONT) for comprehensive TTR gene analysis.

METHODS: We developed an optimized long-range PCR (6,941 bp) followed by ONT MinION sequencing workflow covering the entire TTR gene. Analytical performance was evaluated in two independent diagnostic laboratories using a total of 89 previously characterized samples (64 from laboratory #1 and 25 from laboratory #2). The method was subsequently implemented for routine clinical testing in 445 additional patients referred for suspected ATTRv amyloidosis. Performance metrics, variant detection rates, turnaround time, and concordance with short-read NGS were assessed.

RESULTS: All previously identified pathogenic or likely pathogenic TTR variants were correctly detected, and no false-positive calls. As expected, the most frequent variants were p.(Val142Ile) and p.(Val50Met). Results were fully concordant with short-read NGS. Flowcell washing and reuse considerably lowered reagent costs without compromising an accurate TTR genotyping. Implementation of the ONT workflow reduced turnaround time compared with Illumina-based targeted panels.

CONCLUSIONS: Long-read ONT sequencing of the TTR gene provides a robust, rapid, and economical alternative to conventional methods for genetic diagnosis of ATTRv amyloidosis. The approach we developed is well suited for routine clinical laboratories and supports systematic screening of TTR variants in patients with suspected ATTR.

PMID:42154990 | DOI:10.1515/cclm-2026-0553

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520